Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2023 07:03 ET | Source: atai Life Sciences

atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and data from the EMP-01 (MDMA derivative) Phase 1 study is anticipated to report out later this...
October 06, 2023 16:05 ET | Source: atai Life Sciences

atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
October 02, 2023 16:13 ET | Source: atai Life Sciences

atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

VLS-01, a proprietary oral transmucosal film (OTF) formulation of DMT, was well-tolerated with a favorable safety profilePharmacokinetic and pharmacodynamic data confirmed systemic delivery of DMT via...
September 14, 2023 08:02 ET | Source: atai Life Sciences

atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK and BERLIN, Sept. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
September 06, 2023 16:01 ET | Source: atai Life Sciences

atai Life Sciences to Participate in Upcoming September Investor Conferences

NEW YORK and BERLIN, Sept. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
August 14, 2023 05:10 ET | Source: atai Life Sciences

atai Life Sciences gibt Finanzergebnisse des zweiten Quartals 2023 und operative Highlights sowie klinische Daten aus der Phase-1-Studie mit DMX-1002 (Ibogain) bekannt

Mehrere Wirkstoffe im fortgeschrittenen klinischen Stadium der Entwicklung, einschließlich der laufenden Phase-2b-Studie zu RL-007 für Patienten mit kognitiver Beeinträchtigung im Zusammenhang mit...
August 10, 2023 06:59 ET | Source: atai Life Sciences

atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)

Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients with Cognitive Impairment Associated with SchizophreniaDMX-1002 (Ibogaine) Phase 1...
August 09, 2023 13:53 ET | Source: atai Life Sciences

atai Life Sciences gibt Ergebnisse der Phase-I-Studie zum Übergang von intravenöser zu subkutaner Verabreichung von PCN-101 (R-Ketamin) bekannt

NEW YORK und BERLIN, Aug. 09, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) („atai“), ein im klinischen Stadium tätiges Biopharmazieunternehmen, das nachhaltige Veränderungen in der...
August 08, 2023 16:02 ET | Source: atai Life Sciences

atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

NEW YORK and BERLIN, Aug. 08, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
June 05, 2023 05:49 ET | Source: atai Life Sciences

atai Life Sciences nimmt an kommenden Investorenkonferenzen im Juni teil

NEW YORK und BERLIN, June 05, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) („atai“), ein im klinischen Stadium tätiges Biopharmazieunternehmen, das die Behandlung von psychischen...